Objective:

To present long-term outcomes from the OPTIC trial regarding the efficacy and safety of ixo-vec in treating wet age-related macular degeneration (AMD).

Approach:

Key Findings:

• An 86% average annualized reduction in anti-VEGF injections was observed in years 2, 3, and 4 following treatment.
• The lower dose (2E11) of ixo-vec did not present issues with hypotony, vasculitis, or vascular occlusion.
• Mild cases of intraocular inflammation were treated with topical corticosteroids, indicating manageable safety.

Interpretation:

The data suggest that ixo-vec provides durable efficacy in reducing the need for anti-VEGF injections in wet AMD patients.

Limitations:

• The study primarily focuses on a specific patient population with a history of multiple prior injections.
• Long-term safety and efficacy beyond 4 years remain to be fully established.

Conclusion:

The findings support the continued investigation of ixo-vec in future trials, particularly the phase 2 trial using the lower dose.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.